查詢結果分析
來源資料
相關文獻
- 異體血幹細胞迷你移植(非骨髓破壞之血幹細胞移植)之現況及未來展望
- 洞察捐贈者淋巴球輸注的授受免疫療法
- 異體(週邊)血幹細胞移植最新發展"迷你移植"簡介
- 洞察捐贈者淋巴球輸注的授受免疫療法
- 迷你移植(Mini-Transplantation)
- Allogeneic Bone Marrow Transplantation for Fourteen Patients with Severe Aplastic Anemia
- 骨髓纖維化病患接受異體造血幹細胞移植之預後:單一中心回溯性研究
- 骨髓化生不良症候群2014年臨床處置觀點
- Intravenous Busulfan as Preparative Regimen in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation: The Preliminary Experience in Taiwan
- 異體造血幹細胞移植後移植物抗宿主疾病所引起的皮膚病變及其護理
頁籤選單縮合
題 名 | 異體血幹細胞迷你移植(非骨髓破壞之血幹細胞移植)之現況及未來展望=Nonmyeloablative Hematopoietic Stem Cell Transplantation (Mini-allgrafts): Current Status and Future Prospect |
---|---|
作 者 | 黃文豊; 陳博明; | 書刊名 | 內科學誌 |
卷 期 | 13:5 2002.10[民91.10] |
頁 次 | 頁225-229 |
分類號 | 416.175 |
關鍵詞 | 異體造血幹細胞移植; 植體抗癌作用; 植體對抗宿主疾病; 捐贈者淋巴球輸注; 迷你移植; 非骨髓破壞式移植; Allogeneic stem cell transplantation; GVL; GVM; GVHD; DLI; Mini-transplant; Nonmyeloablative transplant; |
語 文 | 中文(Chinese) |
中文摘要 | 異體造血幹細胞移植可治療許多疾病,包括癌症及非癌症疾病。傳統移植方法,一直使用超高致死劑量之藥物或全身照射治療,以便一舉把所有癌細胞殺死,再輸注異體造血幹細胞 , 以重建病人之骨髓造血功能及兔疫功能,但因使用超高致死劑量,亦伴隨很大之併發症及死亡率,尤其是年齡大的病人及同時罹患其他疾病之病人,皆不適合使用傳統高劑量移植。目前實驗和臨床觀察發現異體移植後,最後根除頑固癌細胞者,乃是移植體抗癌之免疫作用,故新近之移植方法,皆使用毒性小非骨髓破壞劑量之移植,等移植成功後,再藉由移植體抗癌作用,進一步清除剩餘頑固癌細胞或不正常之造血細胞,因為移植前之化療大為減少,故稱為「迷你移植」或「非骨髓破壞式移植」。初步臨床結果發現,可安全適用於年齡大之病人或同時有罹患其他疾病之病人,而且效果不比傳統高劑量移植差,所以未來這種迷你移植將成為傳統高劑量移植外之另一種選擇方式。 |
英文摘要 | Allogeneic hematopoietic stem cell transplantation has proven an effective means of treatment for a variety of malignant and nonmalignant disease. High-dose chemoradiotherapy ( myeloablative ) has been used in conventional allogeneic stem cell transplantation with the goal of preventing graft rejection and eradicating malignancy, which has been associated with high early transplant related mortality and morbidity. This finding has precluded some older or medical co-morbidity patients from being offered stem cell transplantation and has made other populations, such as those with nonmalignant conditions, reluctant to consider this therapy. Much of the benefits of al lo-transplant, however, results from graft-versus leukemia or graft-versus malignancy effect, mediated by donor immunocompetent cells. An alternative approach is to utilize less toxic, nonmyeloablative conditioning for stem cell transplantation. This novel mini-transplantation with nonmyeloablative regimens appear promising in malignancies sensitive to GVL or GVM effect. Preliminary clinical studies have been shown that patients previous ineligible for allogeneic stem cell transplantation can frequently be safely transplanted with good clinical results. |
本系統中英文摘要資訊取自各篇刊載內容。